Establishing Infrastructure for Prevention of familial AD in Mexico
Project Number7R21TW009787-03
Former Number1R21AG043334-01
Contact PI/Project LeaderRINGMAN, JOHN M
Awardee OrganizationUNIVERSITY OF SOUTHERN CALIFORNIA
Description
Abstract Text
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a growing health problem worldwide and currently available treatments are of limited efficacy. Prevention of AD may be a more relevant goal, particularly in lower and middle-income countries. Studies of AD prevention however, are challenging, in part because of the unpredictable onset of the disease in elderly individuals. Persons inheriting mutations causing fully-penetrant autosomal dominant familial AD (FAD) provide an informative and motivated population for assessing the efficacy of AD prevention strategies. The PI has been working with clinician investigators in Mexico for 10 years, characterizing multiple families with FAD due to PSEN1 or APP mutations. Multi-center collaborative efforts to perform prevention trials in preclinical persons carrying FAD mutations are underway (the Dominantly Inherited Alzheimer Network in which the PI is a site investigator and the Alzheimer Prevention Initiative) but such efforts have not reached Mexico. The capacity to perform FAD prevention trials in Mexico may be limited due to lack of understanding among families and physicians of the disease and its genetic nature as well as by the availability of infrastructure including personnel appropriately trained to perform such studies. The goal of this project is to enhance the ability of Mexican investigators to perform such studies through the following specific aims: Aim 1) Enhance local capacity to perform quality cognitive, clinical, imaging, and biochemical assessments as outcome measures for prevention trials in Mexico. This project will be the planning stage in which the possibility of exchange programs wherein health professionals from Mexico come to the UCLA to receive specialty training in dementia diagnosis, management, and research will be explored. Aim 2) Investigate attitudes towards and promote education regarding AD, genetics, FAD, and prevention trial procedures among members of families with FAD in Mexico. Aim 3) Establish a registry of persons eligible for participation in prevention trials for FAD.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE: The goal of this proposal is to facilitate intervention studies to prevent FAD in preclinical mutation carriers in Mexico through a research and training collaboration involving personnel from three institutions: the National Institute for Neurology and
Neurosurgery in Mexico City, the University of Guadalajara, and UCLA. We anticipate that this project will not only facilitate execution of such trials but also facilitate the diagnosis and car of persons with dementia in Mexico in general.
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
989
DUNS Number
072933393
UEI
G88KLJR3KYT5
Project Start Date
01-September-2013
Project End Date
30-April-2018
Budget Start Date
20-May-2016
Budget End Date
30-April-2018
Project Funding Information for 2014
Total Funding
$65,016
Direct Costs
$52,016
Indirect Costs
$13,000
Year
Funding IC
FY Total Cost by IC
2014
John E. Fogarty International Center for Advanced Study in the Health Sciences
$65,016
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R21TW009787-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R21TW009787-03
Patents
No Patents information available for 7R21TW009787-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R21TW009787-03
Clinical Studies
No Clinical Studies information available for 7R21TW009787-03
News and More
Related News Releases
No news release information available for 7R21TW009787-03
History
No Historical information available for 7R21TW009787-03
Similar Projects
No Similar Projects information available for 7R21TW009787-03